PFESeagen, a wholly owned subsidiary of PfizerRunning, no new patients
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 762 (final count)
- Started
- Feb 21, 2024
- Main results expected
- May 18, 2026
- Fully finished
- May 17, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)
Measured over: Approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06012435 · record last updated 2026-07-23 · checked 2026-11-09 15:36 UTC